Sana Biotechnology (SANA) Competitors $2.97 -1.28 (-30.12%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$3.04 +0.07 (+2.36%) As of 08:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SANA vs. CYTK, ZLAB, ADMA, ABVX, RNA, MTSR, AKRO, ACLX, ACAD, and VKTXShould you be buying Sana Biotechnology stock or one of its competitors? The main competitors of Sana Biotechnology include Cytokinetics (CYTK), Zai Lab (ZLAB), ADMA Biologics (ADMA), Abivax (ABVX), Avidity Biosciences (RNA), Metsera (MTSR), Akero Therapeutics (AKRO), Arcellx (ACLX), ACADIA Pharmaceuticals (ACAD), and Viking Therapeutics (VKTX). These companies are all part of the "pharmaceutical products" industry. Sana Biotechnology vs. Its Competitors Cytokinetics Zai Lab ADMA Biologics Abivax Avidity Biosciences Metsera Akero Therapeutics Arcellx ACADIA Pharmaceuticals Viking Therapeutics Sana Biotechnology (NASDAQ:SANA) and Cytokinetics (NASDAQ:CYTK) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment. Do analysts rate SANA or CYTK? Sana Biotechnology presently has a consensus target price of $9.17, suggesting a potential upside of 208.64%. Cytokinetics has a consensus target price of $70.92, suggesting a potential upside of 101.20%. Given Sana Biotechnology's stronger consensus rating and higher possible upside, research analysts clearly believe Sana Biotechnology is more favorable than Cytokinetics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sana Biotechnology 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Cytokinetics 0 Sell rating(s) 4 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 2.88 Do insiders & institutionals hold more shares of SANA or CYTK? 88.2% of Sana Biotechnology shares are owned by institutional investors. 30.1% of Sana Biotechnology shares are owned by company insiders. Comparatively, 2.7% of Cytokinetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has more risk and volatility, SANA or CYTK? Sana Biotechnology has a beta of 1.9, meaning that its stock price is 90% more volatile than the S&P 500. Comparatively, Cytokinetics has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500. Is SANA or CYTK more profitable? Sana Biotechnology has a net margin of 0.00% compared to Cytokinetics' net margin of -3,201.47%. Cytokinetics' return on equity of 0.00% beat Sana Biotechnology's return on equity.Company Net Margins Return on Equity Return on Assets Sana BiotechnologyN/A -86.58% -44.49% Cytokinetics -3,201.47%N/A -43.75% Does the media refer more to SANA or CYTK? In the previous week, Sana Biotechnology had 1 more articles in the media than Cytokinetics. MarketBeat recorded 14 mentions for Sana Biotechnology and 13 mentions for Cytokinetics. Cytokinetics' average media sentiment score of 0.58 beat Sana Biotechnology's score of 0.37 indicating that Cytokinetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sana Biotechnology 2 Very Positive mention(s) 2 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cytokinetics 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation & earnings, SANA or CYTK? Sana Biotechnology has higher earnings, but lower revenue than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSana BiotechnologyN/AN/A-$266.76M-$0.88-3.38Cytokinetics$18.47M227.93-$589.53M-$5.29-6.66 SummarySana Biotechnology beats Cytokinetics on 10 of the 16 factors compared between the two stocks. Get Sana Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for SANA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SANA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SANA vs. The Competition Export to ExcelMetricSana BiotechnologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$958.28M$2.98B$5.48B$9.56BDividend YieldN/A2.46%3.99%4.17%P/E Ratio-3.3817.9729.9325.14Price / SalesN/A179.55375.2276.13Price / CashN/A41.8335.9458.58Price / Book2.657.238.105.59Net Income-$266.76M-$54.43M$3.26B$265.48M7 Day Performance-24.04%0.22%0.68%1.22%1 Month Performance-23.65%5.59%2.45%0.39%1 Year Performance-36.27%9.98%27.72%23.47% Sana Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SANASana Biotechnology3.3016 of 5 stars$2.97-30.1%$9.17+208.6%-37.1%$958.28MN/A-3.38380News CoverageUpcoming EarningsGap DownHigh Trading VolumeCYTKCytokinetics4.1064 of 5 stars$36.63-1.5%$70.92+93.6%-31.2%$4.37B$18.47M-6.92250News CoverageEarnings ReportZLABZai Lab2.5632 of 5 stars$38.69+4.1%$54.28+40.3%+104.7%$4.30B$418.33M-15.541,869News CoveragePositive NewsGap UpADMAADMA Biologics4.2961 of 5 stars$18.00-0.1%$27.67+53.7%+46.3%$4.30B$459.38M21.18530Trending NewsEarnings ReportGap DownABVXAbivax3.4755 of 5 stars$66.57+0.1%$80.00+20.2%+521.8%$4.23BN/A0.0061Upcoming EarningsHigh Trading VolumeRNAAvidity Biosciences2.7695 of 5 stars$34.56-4.7%$66.35+92.0%+15.6%$4.17B$10.90M-11.52190Gap DownHigh Trading VolumeMTSRMetseraN/A$39.43-2.6%$55.00+39.5%N/A$4.14BN/A0.0081Gap DownAKROAkero Therapeutics4.0238 of 5 stars$49.24-2.6%$82.50+67.5%+113.0%$3.93BN/A-25.2530News CoverageInsider TradeACLXArcellx2.635 of 5 stars$70.59-1.0%$111.23+57.6%+39.8%$3.89B$107.94M-23.6180News CoveragePositive NewsEarnings ReportUpcoming EarningsAnalyst RevisionACADACADIA Pharmaceuticals3.9864 of 5 stars$22.62-2.7%$28.13+24.3%+60.8%$3.79B$996.28M16.51510Trending NewsEarnings ReportAnalyst ForecastVKTXViking Therapeutics4.0072 of 5 stars$33.20-3.5%$86.92+161.8%-30.1%$3.73BN/A-21.7020 Related Companies and Tools Related Companies CYTK Competitors ZLAB Competitors ADMA Competitors ABVX Competitors RNA Competitors MTSR Competitors AKRO Competitors ACLX Competitors ACAD Competitors VKTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SANA) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sana Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sana Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
